Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial

This article was originally published here

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the

The post Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply